Crescent Biopharma posts $24.6 million net loss on $20.3 million R&D expenses in Q3 2025

Reuters11-06

Crescent Biopharma posts $24.6 million net loss on $20.3 million R&D expenses in Q3 2025

Crescent Biopharma Inc. reported a net loss of $24.6 million, or $1.27 per basic and diluted share, for the third quarter ended September 30, 2025. Research and development expenses were $20.3 million, while general and administrative expenses totaled $5.5 million for the quarter. The company held cash of $133.3 million as of September 30, 2025, which is expected to fund operations through 2027. As of the end of the quarter, Crescent Biopharma had approximately 19.6 million shares outstanding, including equivalents. During the period, Crescent advanced its oncology pipeline, with an IND submission for CR-001, a PD-1 x VEGF bispecific antibody, on track for the fourth quarter of 2025, aiming to start a global Phase 1 trial in early 2026. An IND submission for CR-002, a novel antibody-drug conjugate, is planned for mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570155-en) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581060631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581060631","market":"fut","top_or_hot":-1,"title":"Crescent Biopharma posts $24.6 million net loss on $20.3 million R&D expenses in Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Crescent Biopharma posts $24.6 million net loss on $20.3 million R&amp;D expenses in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CBIO\">Crescent Biopharma Inc</a>. reported a net loss of $24.6 million, or $1.27 per basic and diluted share, for the third quarter ended September 30, 2025. Research and development expenses were $20.3 million, while general and administrative expenses totaled $5.5 million for the quarter. The company held cash of $133.3 million as of September 30, 2025, which is expected to fund operations through 2027. As of the end of the quarter, Crescent Biopharma had approximately 19.6 million shares outstanding, including equivalents. During the period, Crescent advanced its oncology pipeline, with an IND submission for CR-001, a PD-1 x VEGF bispecific antibody, on track for the fourth quarter of 2025, aiming to start a global Phase 1 trial in early 2026. An IND submission for CR-002, a novel antibody-drug conjugate, is planned for mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570155-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crescent Biopharma posts $24.6 million net loss on $20.3 million R&D expenses in Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrescent Biopharma posts $24.6 million net loss on $20.3 million R&D expenses in Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Crescent Biopharma posts $24.6 million net loss on $20.3 million R&amp;D expenses in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CBIO\">Crescent Biopharma Inc</a>. reported a net loss of $24.6 million, or $1.27 per basic and diluted share, for the third quarter ended September 30, 2025. Research and development expenses were $20.3 million, while general and administrative expenses totaled $5.5 million for the quarter. The company held cash of $133.3 million as of September 30, 2025, which is expected to fund operations through 2027. As of the end of the quarter, Crescent Biopharma had approximately 19.6 million shares outstanding, including equivalents. During the period, Crescent advanced its oncology pipeline, with an IND submission for CR-001, a PD-1 x VEGF bispecific antibody, on track for the fourth quarter of 2025, aiming to start a global Phase 1 trial in early 2026. An IND submission for CR-002, a novel antibody-drug conjugate, is planned for mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570155-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLJJgQy:1","article_id":"2581060631","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581060631","pubTimestamp":1762432277,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Crescent Biopharma Inc. reported a net loss of $24.6 million, or $1.27 per basic and diluted share, for the third quarter ended September 30, 2025. Research and development expenses were $20.3 million, while general and administrative expenses totaled $5.5 million for the quarter. The company held cash of $133.3 million as of September 30, 2025, which is expected to fund operations through 2027. As of the end of the quarter, Crescent Biopharma had approximately 19.6 million shares outstanding, including equivalents. During the period, Crescent advanced its oncology pipeline, with an IND submission for CR-001, a PD-1 x VEGF bispecific antibody, on track for the fourth quarter of 2025, aiming to start a global Phase 1 trial in early 2026. An IND submission for CR-002, a novel antibody-drug conjugate, is planned for mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","CBIO":"Crescent Biopharma Inc","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Crescent Biopharma 2025年第三季度净亏损2460万美元，研发费用为2030万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBIO":0.9,"NDAQ":0.9},"content_text":"Crescent Biopharma posts $24.6 million net loss on $20.3 million R&D expenses in Q3 2025\n    \n\nCrescent Biopharma Inc. reported a net loss of $24.6 million, or $1.27 per basic and diluted share, for the third quarter ended September 30, 2025. Research and development expenses were $20.3 million, while general and administrative expenses totaled $5.5 million for the quarter. The company held cash of $133.3 million as of September 30, 2025, which is expected to fund operations through 2027. As of the end of the quarter, Crescent Biopharma had approximately 19.6 million shares outstanding, including equivalents. During the period, Crescent advanced its oncology pipeline, with an IND submission for CR-001, a PD-1 x VEGF bispecific antibody, on track for the fourth quarter of 2025, aiming to start a global Phase 1 trial in early 2026. An IND submission for CR-002, a novel antibody-drug conjugate, is planned for mid-2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570155-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581060631","isCrawlerRequest":true}